- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07946094
Evaluation of the Effect of Comprehensive Myopia Control Interventions on Myopia Prevention and Control (Evaluation of)
This is a single-center, single-arm, open-label interventional study to evaluate the efficacy of a comprehensive myopia-control regimen in delaying axial elongation and myopia progression in children aged 6-16 years. (Principal investigator: Zhenfei Yang from the Rehabilitation Hospital Affiliated to the National Research Center for Rehabilitation Technical Aids ). The regimen combines five components: (1) myopia-control spectacle lenses incorporating defocus design and Diffusion Optics Technology (DOT); (2) reading-writing glasses that optically relocate near targets to a virtual distance, reducing accommodative lag; (3) nutritional supplements (DHA/EPA, anthocyanins, astaxanthin, vitamin D3 and lutein); (4) repeated low-level red-light (RLRL, 650 nm) therapy; and (5) a distance-viewing device that projects near images to distance. A total of 300 children with myopia will be enrolled and followed for 12 months. The primary outcomes are the change in axial length and the change in cycloplegic spherical equivalent refraction from baseline to 12 months. Safety is monitored throughout by recording adverse events.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Rationale: Myopia prevalence in children is rising globally. Single interventions such as defocus spectacle lenses can slow myopia progression by approximately 40%; reading-writing glasses and distance-viewing devices reduce accommodative lag by optically relocating near targets to distance; nutritional supplements may improve choroidal blood supply and scleral oxygenation, thereby increasing scleral resistance to elongation; and repeated low-level red-light (RLRL) therapy at 650 nm may activate mitochondrial cytochrome c oxidase, enhance retinal pigment epithelium energy metabolism and promote dopamine release, inhibiting axial elongation. This study evaluates whether a combination of these approaches yields better myopia-control efficacy than single measures.
Design and procedures: Eligible children aged 6-16 years with myopia will receive the combined regimen for 12 months, including myopia-control spectacle lenses (defocus + DOT), reading-writing glasses for near work, daily nutritional supplements (DHA/EPA, anthocyanins, astaxanthin, vitamin D3, lutein), RLRL sessions (650 nm, per device instructions), and a distance-viewing device during study-related near tasks. Follow-up visits include ocular examinations, axial length measurement, and cycloplegic refraction. Adverse events are recorded and reported to the institutional ethics committee.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
None Selected
-
Beijing, None Selected, China, 100730
- Werving
- Rehabilitation Hospital Affiliated to the National Research Center for Rehabilitation Technical Aids
-
Contact:
- ZhenFei Yang
- Telefoonnummer: 010-58122901
- E-mail: zfyang2010@126.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged 6-16 years, of either sex;
- Myopia in at least one eye, defined as spherical equivalent refraction (SER) between -0.50 D and -6.00 D measured by comprehensive optometry;
- Astigmatism no more than 2.50 D;
- Corrected visual acuity ≥ 4.9 ;
- No prior use of orthokeratology (OK) lenses, red-light therapy, atropine, or remote-image screens for myopia control; prior use of defocus spectacle lenses is permitted;
- Signed informed consent by guardians and assent by the child (where applicable).
Exclusion Criteria:
- 1. History of any prior myopia-control treatment other than defocus spectacle lenses (orthokeratology, red-light therapy, atropine, remote-image screens, etc.); 2. Strabismus, amblyopia, or other ocular diseases that may affect visual development or measurements (e.g., congenital cataract, glaucoma, retinal or optic nerve disease); 3. Systemic diseases that may affect vision or participation (e.g., diabetes, connective tissue disease, developmental disorders); 4. Inability to comply with the follow-up schedule or use of the intervention devices; 5. Any other condition judged by the investigator as unsuitable for enrollment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: comprehensive myopia control interventions
Participants receive the combined regimen consisting of the five interventions listed below for 12 months |
Participants receive the combined regimen consisting of the five interventions listed below for 12 months |
|
Placebo-vergelijker: control
spectacle lenses |
Participants receive the combined regimen consisting of the five interventions listed below for 12 months |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in axial length from baseline to 12 months
Tijdsspanne: Baseline and 12 months
|
Axial length measured by optical biometry (IOL Master) at baseline and at 12 months; the change (mm) over 12 months is the primary measure of myopia-control efficacy. |
Baseline and 12 months
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Yang ZhenFei myopia
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .